Clinical Application of Glucagon-Like Peptide-1 Receptor Agonists / 임상당뇨병
Journal of Korean Diabetes
;
: 252-259, 2015.
Artigo
em Coreano
| WPRIM
| ID: wpr-726854
ABSTRACT
Glucagon-like peptide 1 (GLP-1) is an incretin hormone that is released from enteroendocrine L-cells upon nutrient absorption; it stimulates glucose-dependent insulin secretion from pancreatic betacells. GLP-1 has pleiotropic effects including deceleration of gastric emptying, decreased appetite, and increased satiety. Treatment with GLP-1 receptor agonists (GLP-1RAs) improves glycemic control in patients with type 2 diabetes without increasing the risk of hypoglycemia or weight gain. Current GLP-1RAs can be classified by their structure (exendin-4-based or human GLP-1-based), duration of action, and molecular size. Different GLP-1RAs exhibit different pharmacokinetics and pharmacodynamics. Herein we review the characteristics of available GLP-1RAs and discuss current issues such as insulin combination therapy and anti-obesity effects.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Apetite
/
Farmacocinética
/
Aumento de Peso
/
Desaceleração
/
Diabetes Mellitus Tipo 2
/
Absorção
/
Peptídeo 1 Semelhante ao Glucagon
/
Incretinas
/
Receptor do Peptídeo Semelhante ao Glucagon 1
/
Esvaziamento Gástrico
Limite:
Humanos
Idioma:
Coreano
Revista:
Journal of Korean Diabetes
Ano de publicação:
2015
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS